Nady Braidy, Yue Liu; Experimental Gerontology, 2020, 110831, doi:10.1016/j.exger.2020.110831.
While these compounds presented with a limited acute toxicity profile, evidence is still quite limited and long-term human clinical trials are still nascent in the current literature. Potential risks in raising NAD+ levels in various clinical disorders using NAD+ precursors include the accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence. Therefore, NAD+ metabolism represents a promising target and further studies are needed to recapitulate the preclinical benefits in human clinical trials.
NOTE: NAD+ and Exercise in FA (ExRx in FA)
Monday, February 10, 2020
Subscribe to:
Posts (Atom)
